G6PD and cancer: A recent study (27) observed that in cancers with NRF2 activation, loss of G6PD activity depleted TCA cycle intermediates as a result of increased malic enzyme and isocitrate dehydrogenase activity and increased the dependence on glutamine as a source of TCA cycle intermediates.